Browse study websites

Discover. Prevent. Cure.

Menu Fundraise Donate

    Recommended pages

      Do you mean

        85-96 of 350 results

        Refine research

        Research

        Erratum to: Exposure to household painting and floor treatments, and parental occupational paint exposure and risk of childhood brain tumors

        This paper corrects an error in data reported in a previous publication. ...

        Research

        Parental occupational exposure to engine exhausts and childhood brain tumors

        Parental occupational exposure to engine exhausts and childhood brain tumors. ...

        Research

        Cancer Survival and Excess Mortality Estimates among Adolescents and Young Adults in Western Australia, 1982-2004: A Population-Based Study

        A cancer diagnosis in adolescents and young adults conferred substantial survival decrement. ...

        Research

        Children's Cancers

        Cancers in children are very different from cancers in adults - in most cases they appear to strike simply at random. They also develop differently and can spread more rapidly and aggressively. And because cancers in children are not obviously linked to their lifestyles, much work is needed to pinpoint their cause. ...

        Research

        Time-course RNAseq data of murine AB1 mesothelioma and Renca renal cancer following immune checkpoint therapy

        Time-critical transcriptional events in the immune microenvironment are important for response to immune checkpoint blockade (ICB), yet these events are difficult to characterise and remain incompletely understood. Here, we present whole tumor RNA sequencing data in the context of treatment with ICB in murine models of AB1 mesothelioma and Renca renal cell cancer.  ...

        Research

        The critical role of the bone marrow stromal microenvironment for the development of drug screening platforms in leukemia

        Extensive research over the past 50 years has resulted in significant improvements in survival for patients diagnosed with leukemia. Despite this, a subgroup of patients harboring high-risk genetic alterations still suffer from poor outcomes. There is a desperate need for new treatments to improve survival, yet consistent failure exists in the translation of in vitro drug development to clinical application. ...

        Research

        Pharmacokinetics of PEGasparaginase in Infants with Acute Lymphoblastic Leukemia

        PEGasparaginase is known to be a critical drug for treating pediatric acute lymphoblastic leukemia (ALL), however, there is insufficient evidence to determine the optimal dose for infants who are less than one year of age at diagnosis. This international study was conducted to identify the pharmacokinetics of PEGasparaginase in infants with newly diagnosed ALL and gather insight into the clearance and dosing of this population. ...

        Research

        FDA-approved disulfiram as a novel treatment for aggressive leukemia

        Acute leukemia continues to be a major cause of death from disease worldwide and current chemotherapeutic agents are associated with significant morbidity in survivors. While better and safer treatments for acute leukemia are urgently needed, standard drug development pipelines are lengthy and drug repurposing therefore provides a promising approach. ...

        Research

        ONC201 in Combination with Paxalisib for the Treatment of H3K27-Altered Diffuse Midline Glioma

        Diffuse midline gliomas (DMG), including diffuse intrinsic pontine gliomas (DIPG), are the most lethal of childhood cancers. Palliative radiotherapy is the only established treatment, with median patient survival of 9 to 11 months. ONC201 is a DRD2 antagonist and ClpP agonist that has shown preclinical and emerging clinical efficacy in DMG.  ...

        Research

        A novel transcriptional signature identifies T-cell infiltration in high-risk paediatric cancer

        Molecular profiling of the tumour immune microenvironment (TIME) has enabled the rational choice of immunotherapies in some adult cancers. In contrast, the TIME of paediatric cancers is relatively unexplored. We speculated that a more refined appreciation of the TIME in childhood cancers, rather than a reliance on commonly used biomarkers such as tumour mutation burden (TMB), neoantigen load and PD-L1 expression, is an essential prerequisite for improved immunotherapies in childhood solid cancers. ...

        Research

        Updates in infant acute lymphoblastic leukemia and the potential for targeted therapy

        Outcomes for infants diagnosed under 1 year of age with KMT2A-rearranged acute lymphoblastic leukemia (ALL) have remained stagnant over the past 20 years. Successive treatment protocols have previously focused on intensification of conventional chemotherapy, but increased treatment-related toxicity and chemoresistance have led to a plateau in survival. ...

        Research

        RaScALL: Rapid (Ra) screening (Sc) of RNA-seq data for prognostically significant genomic alterations in acute lymphoblastic leukaemia (ALL)

        RNA-sequencing (RNA-seq) efforts in acute lymphoblastic leukaemia have identified numerous prognostically significant genomic alterations which can guide diagnostic risk stratification and treatment choices when detected early. ...

        Page 8 of 30